



INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY *of* WASHINGTON

Meeting Minutes

Date: Wednesday, August 17, 2022

Time: 10:00 AM – 12:00 PM

Location: Zoom and Magnuson Health Sciences Building T-269

Members

- Present:**
1. Jason Cantera (*Community Member*)
 2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
 3. Lesley Decker, Environmental Health & Safety (*Biosafety Officer*)
 4. Erin Heiniger, Department of Bioengineering (*Laboratory Specialist*)
 5. Richard Grant, Washington National Primate Research Center
 6. Kevin Hybiske, Allergy and Infectious Diseases (*IBC Vice Chair*)
 7. David Koelle, Allergy and Infectious Diseases
 8. Stephen Libby, Laboratory Medicine (*Animal Containment Expert*)
 9. Scott Meschke, Environmental & Occupational Health Sciences
 10. Susan Parazzoli (*Community Member*)
 11. Jason Smith, Microbiology (*IBC Chair*)
 12. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)
 13. Elyse Verstelle, Department of Immunology (*Laboratory Specialist*)

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

NHP: non-human primate

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 a.m. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
 - The IBC Chair sought a motion to approve the minutes from the July 20, 2022, meeting.
 - A member made a motion to approve the July 20, 2022, minutes. Another member seconded the motion.
 - The committee voted to approve the July 20, 2022, meeting minutes, with two members abstaining.
4. **OLD BUSINESS:**
 - At the July 20, 2022, meeting, Dr. Bornfeldt's BUA was approved pending review of the IACUC protocol. This BUA has been sent out.
 - At the July 20, 2022, meeting, Dr. Elkon's BUA was approved pending a lab inspection response. This BUA has been sent out.
 - At the July 20, 2022, meeting, Dr. Giachelli's BUA was approved pending their written BSL-2 with BSL-3 practices SOP. This BUA has been sent out.
 - At the July 20, 2022, meeting, Dr. Macks's BUA was approved pending the lab inspection. This BUA is still pending.
 - At the July 20, 2022, meeting, Dr. Ojo's BUA was approved pending clarification of aerosolization risk from sonication. This BUA has been sent out.
 - At the July 20, 2022, meeting, Dr. Phillip's BUA was approved pending successful completion of the lab inspection. This BUA is still pending.
 - At the July 20, 2022, meeting, Dr. Poolos's BUA was approved pending lab inspection response and training. This BUA is still pending.
 - At the July 20, 2022, meeting, Dr. Riffell's BUA was approved pending lab inspection. This BUA is still pending.
 - At the July 20, 2022, meeting, Dr. Ruohola-Baker's BUA was approved pending lab inspection and review of the IACUC protocol. This BUA is still pending.
 - At the July 20, 2022, meeting, Dr. Yang's BUA was approved pending a lab inspection response. This BUA has been sent out.
 - At the July 20, 2022, meeting, Dr. Koelle's BUA was approved pending completion of an occupational health review and lab inspection responses. This BUA is still pending.
5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
 - a. Biosafety Officer Report
 - Dr. Murry added human cells that tested negative for BBP and LCMV in rats at ABSL-1 to the BUA *Myocardial Infarct Repair in Rats*.
 - Dr. Erasmus added the use of non-recombinant Enterovirus B in mice to the BUA *RNA Vaccines*.

- Dr. Grady renewed his work for handling human blood and slides of fixed tissue on the BUA *Gastrointestinal Cancer Resource (GICaRes) Biorepository*.
- Dr. Hu added in vitro rooms at the Health Sciences Building and removed rooms at the Western Facility for work with previously approved agents to the BUA *HIVRAD: Core B: Virology/Immunology*.
- Dr. Hu added in vitro rooms at the Health Sciences Building and removed rooms at the Western Facility for work with previously approved agents to the BUA *Glycan modification, CD4 independence, and Env Immunogenicity*.
- Dr. Hu added in vitro rooms at the Health Sciences Building and removed rooms at the Western Facility for work with previously approved agents to the BUA *Virus-like particles (VLP) with stabilized trimeric envelope (ENV) for prime-boost immunization*.
- Dr. Lood renewed the BUA *Neutrophil contribution to inflammation and autoimmunity in rheumatic diseases* for in vitro work with clinical samples from patients suspected to be infected with COVID-19, and recDNA.
- Dr. Adams Waldorf renewed the BUA *Influenza and Coronavirus Model of Immunity in Pregnancy for working with influenza virus*, in vitro and in vivo in Macaque in addition to; recDNA, human and non-human primate cells, and clinical samples from patients suspected to be infected with COVID-19 in vitro.
- Dr. Limaye renewed the BUA *Limaye Clinical Research* for in vitro work with human cell lines and clinical samples from patients suspected to be infected with COVID-19.
- Dr. Fuhmeister was approved for in vitro work with several bacterial strains and recDNA on the BUA *Environmental Reservoirs of Enteric Pathogens and Antimicrobial Resistance*.
- Dr. Fuller added new gene inserts to recDNA for use in vivo use in mice to the BUA *DNA Vaccine Therapy*.
- Dr. Murphy added non-human primate stool for analysis to the BUA *NHP Study*.
- Dr. Disis added several species of non-recombinant bacteria for in vivo use in mice at ABSL-1 to the BUA *Evaluation of Immunity to Cancer in a Rodent Model*.
- Dr. Fuller added wildtype SIV and recombinant SIV as "primate lentivirus" in vitro and in vivo in non-human primates to the BUA *Nucleic Acid Mediated Protein Expression* The recombinant SIV was reviewed by the IBC on another Fuller BUA in 2021.
- The IBC Chair a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report.

6. **BSL-3 INACTIVATION REPORT**

- Dr. Sims requested inactivation of SARS-CoV-2 samples by DDM treatment (n-dodecyl-beta-maltoside detergent extraction) with a heat treatment step. This request followed an inactivation failure of the DDM treatment without the heat treatment step.
- The subcommittee reviewed procedure and inactivation data provided by the lab and approved the request.
- The IBC Chair a motion to approve this month's BSL-3 Inactivation Report.
- A member made a motion to approve this month's BSL-3 Inactivation Report. Another member seconded the motion.
- The committee voted unanimously to approve this month's BSL-3 Inactivation Report.

7. INDIVIDUAL PROJECT REVIEWS

- a. Basso, Michele, change, *The neurophysiology of decision making during uncertainty*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - The Basso lab is adding a third generation lentiviral vector and Cre construct.
 - A lab inspection was not required as all work takes place inside a vivarium.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Basso.
The Committee voted unanimously to approve the draft BUA for Dr. Basso.

- b. Basso, Michele, change, *Brain circuits of perceptual decision-making in mice*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - The Basso lab is adding rooms and third generation lentiviral vector.
 - The lab was inspected, and all deficiencies have been corrected.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Basso.
 - The Committee voted unanimously to approve the draft BUA for Dr. Basso

- c. Chao, Jennifer, renewal, *In vitro models of retinal degenerative diseases*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - The Chao lab aims to establish in vitro models of retinal degenerative diseases and to use the models to screen for pro-survival drug compounds.
 - The lab works with lentiviral vectors and human tissue, blood, and cell lines.
 - The lab was inspected, and all deficiencies have been corrected.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chao.
The Committee voted to approve the draft BUA for Dr. Chao, with one member not submitting a vote.

- d. Chatterjee, Champak, renewal, *Histone SUMOylation*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - The Chatterjee lab aims to understand the protein SUMO's effect on chromatin compaction, and the modification of chromatin by other enzymes.
 - The lab works with E. coli, human cell lines and viral vectors.
 - A lab inspection has been performed and is still pending a response.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chatterjee.
 - The Committee voted unanimously to approve the draft BUA for Dr. Chatterjee pending successful completion of the lab inspection.

- e. Darveau, Richard, renewal, *Healthy Homeostasis/P. gingivalis virulence/Neutrophil migration*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Darveau lab aims to determine the bacterial mechanisms involved in promoting the development of periodontal disease
 - This lab works with human cell lines and several species of Risk Group 2 bacteria.
 - The lab inspection is scheduled for after the IBC meeting.
 - The required trainings are still pending.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Darveau. The Committee voted unanimously to approve the draft BUA for Dr. Darveau pending successful completion of the lab inspection.
- f. Doherty, Dan, renewal, *Joubert Syndrome and Related Disorders*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The aim of the Doherty lab is to identify genetic causes of human brain malformations and study the molecular mechanisms underlying these disorders.
 - This lab works with human blood, tissues and cells, Epstein-Barr virus and lentiviral vectors.
 - The lab inspection was inspected, and all deficiencies have been corrected.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Doherty. The Committee voted to approve the draft BUA for Dr. Doherty, with one member not submitting a vote.
- g. Ferreira, Manuel, renewal, *Tissue Bank for the Investigation of the Genetics and Basic Biology of Human Vascular Malformations and Skull-Base Tumors*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Ferreira Lab aims to understand the biology of diseases that cause vascular malformation and brain tumors.
 - This lab works with human blood and tissue, lentiviral vectors and recombinant RNA.
 - The lab was inspected, and all deficiencies have been corrected.
 - The required trainings are still pending.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ferreira. The Committee voted unanimously to approve the draft BUA for Dr. Ferreira pending completion of the required trainings.
- h. Fields, Stanley, renewal, *Development of Protein and Nucleic Acid Technologies*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Fields lab aims to develop new technologies to better understand the function and activities of DNA, RNA and proteins.
 - The lab works with transgenic worms and sea squirts.
 - The lab was inspected, and all deficiencies have been corrected.
 - All required trainings are complete.

- The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Fields.
The Committee voted unanimously to approve the draft BUA for Dr. Fields.
- i. James, Richard, renewal, *Persistence of immune cell*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The James lab aim is to engineer primate B cells and evaluate their persistence.
 - The lab works with adeno-associated viral vectors and primary non-human primate cells.
 - The lab inspection is scheduled for after the IBC meeting.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. James.
The Committee voted unanimously to approve the draft BUA for Dr. James pending successful completion of the lab inspection.
- j. Kiem, Hans-Peter, renewal, *Strategies to Improve Hematopoietic Stem Cell Transduction*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Kiem lab aims to use the non-human primate model to study gene therapy as a treatment modality for genetic disorders and acquired diseases such as AIDS and cancer.
 - The lab works with adeno-associated viral vectors, lentiviral vectors, primate lentivirus and non-human primate cells.
 - A lab inspection was not required as all work takes place inside a vivarium.
 - All required trainings are complete.
 - The IACUC protocol is still pending.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kiem.
The Committee voted unanimously to approve the draft BUA for Dr. Kiem.
- k. King, Mary-Claire, renewal, *King Lab Research (renewal)*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The King lab aims to discover genes responsible for complex traits in humans
 - The lab cultures human cell lines with Epstein-Barr virus and uses Sendai viral vectors to create induced pluripotent stem cells.
 - The lab was inspected, and all deficiencies have been corrected.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. King.
The Committee voted unanimously to approve the draft BUA for Dr. King.
- l. Kublin, James, renewal, *Role of the microbiome in HIV vaccine induced heterogeneity*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Kublin lab aims to understand how the gut microbiome shapes immune responses to HIV vaccines and contributes to vaccine response heterogeneity.
 - The lab's work includes injecting mice with different species of Risk Group 1 and 2 bacteria, recombinant DNA vaccines and the ALVAC canary-pox vaccine.

- There was a discussion about coxsackie viruses, and it was determined that they should be listed as Enterovirus type B for consistency with other approvals.
 - A lab inspection was not required as all work takes place inside a vivarium.
 - All required trainings are complete.
 - This project has an IACUC protocol in review
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kublin. The Committee voted unanimously to approve the draft BUA for Dr. Kublin pending edits to the BUA and corrections to the BUA letter.
- m. Ong, Shao-En, renewal, *Defining Pathway-Specific Kinase Signaling Modules with Proteomics*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Ong lab aims to identify phosphosignatures of cell signaling pathways for clinical diagnostics.
 - The lab works with human tissue and cell lines.
 - The lab was inspected, and all deficiencies have been corrected.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ong. The Committee voted unanimously to approve the draft BUA for Dr. Ong pending addition of HEK293 cells to the BUA application.
- n. Sanchez-Contreras, Monica, change, *Contribution of somatic mitochondrial DNA mutation to the transition from normal aging to Alzheimer's disease*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Sanchez-Contreras lab is adding use of adeno-associated viral vectors in mice.
 - A lab inspection was not required.
 - All required trainings are complete.
 - This project has an IACUC protocol in review
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sanchez-Contreras. The Committee voted unanimously to approve the draft BUA for Dr. Sanchez-Contreras.
- o. Seshadri, Chetan, renewal, *Immune Profiling in Infectious Diseases*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Seshadri lab aims to understand why people have varying susceptibility to infections like tuberculosis for improved treatment strategies.
 - The lab's research involves working with human and non-human primate blood samples and lentiviral vectors.
 - There was a discussion about the comprehensiveness of the BUA application. It was decided that the BUA application did not provide enough information for IBC review at this time.
 - The lab was inspected, and no deficiencies were noted.
 - The required trainings are still pending.
 - The draft BUA letter was not shown.

- The IBC Primary Reviewer made a motion to review an updated draft BUA at the next IBC meeting for Dr. Seshadri.
The Committee voted unanimously to approve review of an updated draft BUA at the next IBC meeting for Dr. Seshadri.
- p. Sniadecki, Nathan, renewal, *Studies on Cell Mechanics and Mechanotransduction with Engineered Systems*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Sniadecki lab aims to better understand the mechanics of biological cells.
 - The lab works with human blood and cells, induced pluripotent stem cells and adeno-associated viral vectors.
 - A lab inspection has been performed and is still pending a response.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sniadecki.
 - The Committee voted unanimously to approve the draft BUA for Dr. Sniadecki pending successful completion of the lab inspection.
- q. Sullivan, Jane, renewal, *Cellular and Molecular Mechanisms of Synaptic Transmission*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The Sullivan lab aims to understand cellular and molecular mechanisms that control normal and pathological communication between brain cells.
 - The lab works with third generation lentiviral vectors and adeno-associated viral vectors.
 - There was a discussion about removing lentiviral vector production from the BUA application since no human cell lines required for production are currently used by the lab.
 - The lab was inspected, and no deficiencies were noted.
 - All required trainings are complete.
 - This project has an IACUC protocol in review.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sullivan.
The Committee voted unanimously to approve the draft BUA for Dr. Sullivan pending BUA application edit.

8. SUBCOMMITTEE REPORTS:

- r. Greninger, Alex, new, *Monkeypox Viral Isolation from Clinical Specimens*
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
 - The Greninger lab aims to culture monkeypox virus from clinical specimens from patients infected with monkeypox virus to establish virus viability.
 - The lab will culture clinical monkeypox specimens in non-human primate cells. The specimens are expected to contain only monkeypox virus from the West African clade as this is the clade circulating in the current outbreak.
 - A lab inspection was not required as the lab was recently inspected.
 - All required trainings are complete.

- A medical management plan is in progress for monkeypox.
 - The draft BUA letter was shown.
 - A member made a motion to approve the draft BUA letter for Dr. Greninger. Another member seconded the motion.
 - The Committee voted unanimously to approve the draft BUA for Dr. Greninger pending the completion of the medical management plan for monkeypox.
- s. Hall, Evan, new, *An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MED19253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors*
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
 - This is a clinical study to assess the safety, tolerability, and dose and schedule of administration of a recombinant Newcastle disease viral vector encoding interleukin-12 in combination with a current drug treatment for the treatment of select advanced/metastatic solid tumors.
 - All required trainings are complete.
 - The draft BUA letter was shown.
 - A member made a motion to approve the draft BUA letter for Dr. Hall. Another member seconded the motion.
 - The Committee voted unanimously to approve the draft BUA for Dr. Hall.

10. FOR YOUR INFORMATION:

- Public Meetings Act training video will be shown at the September IBC meeting

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS: There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 11:51 P.M.